RNF6 and colorectal carcinoma: Given that RNF6 confers drug resistance towards 5-FU while concomitantly promoting sensitivity to pladienolide B, we reasoned that the combination of 5-FU plus pladienolide B could be a promising strategy for targeting CRC with high RNF6 expression.